Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Better Gout Trials Might Look Like

Executive Summary

FDA comments in Ironwood's Zurampic review suggest what the agency would like to see from gout clinical programs.

Advertisement

Related Content

Drug Review Profiles: Behind The Scenes At US FDA
US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews
With Zurampic, FDA Again Made Do With Sorry State Of Regulatory Science In Gout

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118952

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel